Effectiveness of different eradication treatment protocols for new‐onset Pseudomonas aeruginosa in children with cystic fibrosis. Issue 6 (8th April 2022)

• Record Type: Journal Article
• Authors: Sunman, Birce; Emiralioglu, Nagehan; Hazirolan, Gülsen; Şener, Burçin; Ozsezen, Beste; Tural, Dilber A.; Buyuksahin, Halime N.; Guzelkas, Ismail; Yalcin, Ebru; Dogru, Deniz; Özçelik, Uğur; Kiper, Nural
• Is Part Of: Pediatric pulmonology. Volume 57:Issue 6(2022)
• Page Start: 1456
• Page End: 1465
• Publication Date: 2022-04-08
• Subjects: children -- cystic fibrosis -- inhalation -- intravenous -- Pseudomonas aeruginosa; Pediatric respiratory diseases -- Periodicals; Pediatrics -- Periodicals; 618.922
• DOI: 10.1002/ppul.25876
• Languages: English
• ISSNs: 8755-6863

Abstract

Abstract: Objectives: While eradicating new‐onset Pseudomonas aeruginosa in children with cystic fibrosis is an important issue, there is no clear evidence about the best treatment approach. This retrospective observational cohort study aims to compare the effectiveness of intravenous therapy versus inhalation with/without oral therapy in the eradication of new‐onset P. aeruginosa, determine the factors affecting the treatment success and assess lung function at baseline and posttreatment. Methods: Of 399 children, 110 (140 episodes) with either the first P. aeruginosa isolation or a new isolation after at least 1 year free of infection were included. Different eradication regimens (intravenous therapy or inhaled tobramycin or inhaled tobramycin plus oral ciprofloxacin) were compared. Eradication success was accepted as remaining free of infection with a negative culture for 12 months. Demographic, clinical, and microbiological characteristics of children, effectiveness of different eradication strategies, time to a new P. aeruginosa isolation, and the relationship between lung function and the type of eradication regimen were determined. Results: Of 140 episodes, intravenous therapy was administered in 53 and inhalation therapy (in combination with or without oral ciprofloxacin) in 87. Total success rate of eradication was 60.7%. Eradication was achieved in 56.6% of children with intravenous therapy, 59.7% with inhaled tobramycin therapy, and 72% with inhaled tobramycin plus oral ciprofloxacin therapy. Success rates of different eradication regimens did not differ significantly ( p = 0.419). Lung function by the end of the first year was worse in the intravenous group compared to the inhalation group ( p = 0.017 for forced expiratory volume in 1 s, p = 0.015 for forced vital capacity). Conclusion: No advantage of intravenous therapy was demonstrated compared to inhalation therapy in terms of eradication success.